Journal article

Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme.

Kamlesh Khunti, Hungta Chen, Javier Cid-Ruzafa, Peter Fenici, Marilia B Gomes, Niklas Hammar, Linong Ji, Mikhail Kosiborod, Stuart Pocock, Marina V Shestakova, Iichiro Shimomura, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, undefined DISCOVER investigators

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics | Published : 2020

Abstract

AIM: To assess glycaemic control and factors associated with poor glycaemic control at initiation of second-line therapy in the DISCOVER programme. MATERIALS AND METHODS: DISCOVER (NCT02322762 and NCT02226822) comprises two similar prospective observational studies of 15 992 people with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy in 38 countries across six regions (Africa, Americas, South-East Asia, Eastern Mediterranean, Europe and Western Pacific). Data were collected using a standardized case report form. Glycated haemoglobin (HbA1c) levels were measured according to standard clinical practice in each country, and factors associated with poor glycaemic control (H..

View full abstract

University of Melbourne Researchers